NewAmsterdam Pharma Co N.V. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone Q4 filing; the supplied filing text does not provide separate Q4 results. Financial statements are prepared under IFRS and presented in euros.
Business context
NewAmsterdam is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Its primary candidate, obicetrapib, is an oral CETP inhibitor being developed to lower LDL-C, alone and with ezetimibe. The company completed its business combination with Frazier Lifesciences Acquisition Corporation (FLAC) and began trading on Nasdaq in November 2022. It reported 81.6 million ordinary shares outstanding at year-end.
Key financial metrics
| € millions, except per-share data | FY2022 | FY2021 |
|---|---|---|
| Revenue | 97.5 | — |
| Research and development expense | 82.2 | 25.0 |
| Selling, general and administrative expense | 22.2 | 4.8 |
| Share-listing expense | 60.6 | — |
| Operating loss | 67.6 | 29.8 |
| Net loss | 78.1 | 28.6 |
| Basic and diluted loss per share | €0.96 | €1.19* |
| Net cash from/(used in) operating activities | 8.0 | (25.2) |
| Cash at year-end | 438.5 | 53.1 |
*FY2021 per-share amount is restated for the business-combination exchange ratio. No meaningful product gross margin is reported; 2022 revenue was licensing revenue, not product sales. The filing does not provide a comparable standalone Q4 margin or cash-flow figure.
- Revenue quality: €93.5 million was recognized for the Menarini license and €4.0 million for research and development services under that agreement. A further €17.5 million remained deferred at year-end (€13.0 million current; €4.5 million non-current). No product-sale revenue was reported.
- Cash generation and funding: Positive operating cash flow reflected the Menarini upfront payment and deferred-revenue movements, while the company remained loss-making. Financing cash flow was €375.2 million, chiefly from the Series A second tranche and the business combination/PIPE financing. Cash increased by €385.4 million.
- Balance sheet and liquidity: Total assets were €531.6 million, equity €484.5 million, and accumulated losses €119.4 million. Trade and other payables were €18.5 million; lease liabilities totaled €0.1 million. The filing reports no outstanding conventional borrowings at year-end. Derivative warrant and earnout liabilities were €3.9 million and €7.1 million, respectively.
- Foreign exchange: The company recorded a €9.3 million foreign-exchange loss, primarily associated with U.S.-dollar cash and U.S.-dollar R&D spending. Its net foreign-currency exposure was €268.2 million, mainly U.S. dollars.
Material changes versus FY2021
- Revenue rose from zero to €97.5 million, primarily from the Menarini license. The company recognized €115.0 million upfront in July 2022, allocating €93.5 million to the license and €21.5 million to R&D services; €4.0 million of the latter was recognized during 2022.
- R&D expense increased 228% to €82.2 million, including higher Phase 3 trial costs; SG&A rose to €22.2 million amid public-company transition, transaction, personnel and advisory costs.
- The €60.6 million non-cash share-listing expense arose from accounting for the FLAC combination under IFRS 2. Net loss increased to €78.1 million despite license revenue.
- Cash rose from €53.1 million to €438.5 million following the €79.7 million Series A second tranche, business-combination proceeds and PIPE financing.
Outlook, commentary and risks
- Management said existing cash, including the Menarini upfront payment, was expected to fund the anticipated operating plan through 2026. The company nevertheless expects substantial ongoing losses and may need additional capital depending on trial costs, timelines and other needs.
- At filing, management expected BROADWAY and BROOKLYN Phase 3 lipid-trial data in 2024 and PREVAIL cardiovascular-outcomes data in 2026. It expected 2023 results from the Japan Phase 2 study and the Alzheimer’s Phase 2a study. These are forward-looking expectations, not guarantees.
- In January 2023, after year-end, the company announced positive topline ROSE2 results: obicetrapib plus ezetimibe reduced median LDL-C by 59% versus 6% with placebo; the company expected a €5 million Menarini milestone payment by April 2023. These are subsequent events, not FY2022 revenue.
- Menarini’s European license includes up to €863 million in additional clinical, regulatory and commercial milestones and tiered sales royalties; these are contingent and not assured. The €27.5 million development-funding commitment was constrained and not recognized in the initial transaction price.
- Key risks include dependence on obicetrapib, clinical and regulatory uncertainty, competition, reliance on third-party manufacturing and clinical vendors, commercial execution and reimbursement. The company also disclosed that substantially all funds were held at three financial institutions and could exceed deposit-insurance limits; it stated it had no deposits or borrowing arrangements with Silicon Valley Bank or Signature Bank.
- Financial reporting controls: Management identified material weaknesses across the COSO control framework, reported that a material misstatement had been corrected, and concluded disclosure controls were ineffective at December 31, 2022. Remediation plans included hiring finance/IT resources, formalizing controls, implementing an ERP system and establishing continuous risk assessment.
- The auditor issued an unqualified opinion on the IFRS financial statements. The auditor did not opine on internal-control effectiveness; no auditor attestation was included.
Important facts for investors to verify
- Reconcile the €97.5 million reported revenue to Menarini contract accounting, deferred revenue and future development reimbursements; distinguish recognized revenue from cash receipts and contingent amounts.
- Track cash burn excluding upfront and financing proceeds, trial spending, contractual service commitments (estimated cancellation exposure of up to €16.6 million within one year and €5.1 million thereafter), and management’s cash-runway assumptions.
- Confirm progress and results for BROADWAY, BROOKLYN and PREVAIL, regulatory requirements, safety findings, and whether the clinical timetable or trial costs have changed.
- Assess remediation of the disclosed material weaknesses, including whether controls are operating effectively and whether future filings identify further errors or weaknesses.
- Review dilution and resale overhang: 4.767 million warrants were outstanding at year-end, and the filing registered substantial shareholder resales. Verify subsequent exercises, sales, lock-up expirations and share-count changes.
- Consider the disclosed potential PFIC status for U.S. taxpayers and consult a tax adviser regarding reporting and elections.